Impact of Body Mass Index on Progression of Primary Immunoglobulin A Nephropathy

Nagaraju, Shankar Prasad and Dharshan, R and Srikanth, Prasad and Kaza, Sindhu and Shenoy, Srinivas Vinayak and Saraf, Karan and Prabhu, Ravindra A and Guddattu, Vasudeva and Koulmane, Sindhura LL (2018) Impact of Body Mass Index on Progression of Primary Immunoglobulin A Nephropathy. Saudi Journal of Kidney Diseases and Transplantation, 29 (2). pp. 318-325. ISSN 1319-2442

[img] PDF
5763 DisplayPdf.pdf - Published Version
Restricted to Registered users only

Download (164kB) | Request a copy


The role of obesity in the progression of primary glomerular diseases is controversial. A few studies report overweight/obesity as a risk factor for disease progression in immunoglobulin A nephropathy (IgAN), and the real impact of it still remains unclear. The aim of this study was to elucidate the effect of body mass index (BMI) on disease progression and proteinuria in patients with IgAN in Indian population. A cohort of biopsy-proven primary IgAN patients diagnosed between March 2010 and February 2015 who had a follow-up for a minimum of 12 months were included in the study. We defined two groups of patients according to the BMI value at diagnosis: non-obese group (Group N) with BMI <23 Kg/m2 and the overweight/obese group (Group O) with BMI >23 Kg/m2 as per Asia-Pacific task force criteria. Baseline characteristics were compared between the groups. The estimated glomerular filtration rate (eGFR) and urine protein-creatinine ratio (UPCR) were followed up at entry time, 6 months, 12 months, and at the end of follow-up. Outcomes studied were change in eGFR, proteinuria, and progression to end-stage renal disease. Statistical analysis was done using the Statistical Package for the Social Sciences version 15.0. Of 51 patients, 25 (49%) had BMI <23 kg/m2 (Group N) and 26 (51%) had BMI >23 kg/m2 (Group O) (P = 0.01). The baseline clinical, histopathological, and treatment characteristics of both the groups were comparable. The BMI at the time of diagnosis did not have any significant effect on eGFR (P = 0.41) or proteinuria (P = 0.99) at presentation. At the end of follow-up, both the groups had a similar reduction of proteinuria (UPCR) (P = 0.46) and eGFR (P = 0.20). Two patients in each group have reached chronic kidney disease Stage 5. In the present study, BMI at presentation did not have any impact on eGFR or proteinuria, either at diagnosis or at follow-up. It needs further large multicenter randomized control studies to see the effect of BMI on progression of IgAN.

Item Type: Article
Subjects: Departments at MU > Statistics
Medicine > KMC Manipal > Nephrology
Medicine > KMC Manipal > Pathology
Depositing User: KMC Library
Date Deposited: 12 Jan 2019 09:31
Last Modified: 12 Jan 2019 09:31

Actions (login required)

View Item View Item